{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-020652","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2025-06-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.222827+00:00","generated_at":"2026-05-19T05:11:30.747468+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Allarity shareholders reject equity plan increase and officer exculpation","bullets":["Thomas H. Jensen re-elected as Class III director with 1,673,698 for, 265,465 withheld.","Ratification of Wolf & Company as auditor passed with 6,706,148 votes for.","Proposal to increase 2021 Plan shares from 717,941 to 3,415,068 failed (928,978 for vs 932,866 against).","Amendment to limit officer liability (Officer Exculpation) also did not pass (1,359,331 for vs 563,585 against).","Adjournment proposal approved 4,976,159 for, 1,924,694 against; quorum was 41% of outstanding shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-020652","json":"https://secwatch.observer/filing/0001437749-25-020652.json","markdown":"https://secwatch.observer/filing/0001437749-25-020652.md","text":"https://secwatch.observer/filing/0001437749-25-020652.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000143774925020652/0001437749-25-020652-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000143774925020652/allr20250617_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T05:11:30.747468+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}